Nathaniel Brooks Horwitz
Biomedical Venture Capitalist
Biotechnology is ascendant. Advances in biology have converged with progress in computation, engineering and finance to enable biotechnology that was until recently mere science fiction.
I study the science, business and ethics of biotech. As CEO of Nivien Therapeutics, I led development of an experimental therapy for pancreatic cancer. I now serve as a Principal at RA Capital and on the boards of six companies, including Synthego, Quench Bio, Genti Bio and others in stealth. I also served on the boards of Clear Creek Bio and Eliem Therapeutics.
My drug target discovery research is published in Cell and writing in The Washington Post, New York Times, Boston Globe and The Atlantic. My opinions are my own and do not represent RA Capital.